Cargando…
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698871/ https://www.ncbi.nlm.nih.gov/pubmed/31557983 http://dx.doi.org/10.3390/antib5010001 |
_version_ | 1783444632514854912 |
---|---|
author | Del Bano, Joanie Chames, Patrick Baty, Daniel Kerfelec, Brigitte |
author_facet | Del Bano, Joanie Chames, Patrick Baty, Daniel Kerfelec, Brigitte |
author_sort | Del Bano, Joanie |
collection | PubMed |
description | As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the “bispecifics” market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests. Furthermore, perspectives of bispecific antibodies in future clinical developments are addressed. |
format | Online Article Text |
id | pubmed-6698871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66988712019-09-05 Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Del Bano, Joanie Chames, Patrick Baty, Daniel Kerfelec, Brigitte Antibodies (Basel) Review As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the “bispecifics” market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests. Furthermore, perspectives of bispecific antibodies in future clinical developments are addressed. MDPI 2015-12-26 /pmc/articles/PMC6698871/ /pubmed/31557983 http://dx.doi.org/10.3390/antib5010001 Text en © 2015 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Del Bano, Joanie Chames, Patrick Baty, Daniel Kerfelec, Brigitte Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? |
title | Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? |
title_full | Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? |
title_fullStr | Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? |
title_full_unstemmed | Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? |
title_short | Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? |
title_sort | taking up cancer immunotherapy challenges: bispecific antibodies, the path forward? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698871/ https://www.ncbi.nlm.nih.gov/pubmed/31557983 http://dx.doi.org/10.3390/antib5010001 |
work_keys_str_mv | AT delbanojoanie takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward AT chamespatrick takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward AT batydaniel takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward AT kerfelecbrigitte takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward |